- Home
- WFRD vs GRFS Comparison
WFRD vs GRFS Comparison
Compare WFRD & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFRD
- GRFS
- Stock Information
- Founded
- WFRD 1941
- GRFS 1940
- Country
- WFRD United States
- GRFS Spain
- Employees
- WFRD N/A
- GRFS N/A
- Industry
- WFRD Metal Fabrications
- GRFS Biotechnology: Pharmaceutical Preparations
- Sector
- WFRD Industrials
- GRFS Health Care
- Exchange
- WFRD Nasdaq
- GRFS Nasdaq
- Market Cap
- WFRD 5.2B
- GRFS 5.5B
- IPO Year
- WFRD N/A
- GRFS 2006
- Fundamental
- Price
- WFRD $65.48
- GRFS $7.45
- Analyst Decision
- WFRD Strong Buy
- GRFS Strong Sell
- Analyst Count
- WFRD 9
- GRFS 1
- Target Price
- WFRD $122.44
- GRFS N/A
- AVG Volume (30 Days)
- WFRD 1.5M
- GRFS 789.1K
- Earning Date
- WFRD 02-05-2025
- GRFS 01-01-0001
- Dividend Yield
- WFRD 1.14%
- GRFS N/A
- EPS Growth
- WFRD 19.26
- GRFS N/A
- EPS
- WFRD 6.75
- GRFS 0.27
- Revenue
- WFRD $5,513,000,000.00
- GRFS $7,814,096,584.00
- Revenue This Year
- WFRD $0.13
- GRFS $9.53
- Revenue Next Year
- WFRD $4.38
- GRFS $8.09
- P/E Ratio
- WFRD $9.76
- GRFS $33.40
- Revenue Growth
- WFRD 7.36
- GRFS 7.21
- 52 Week Low
- WFRD $60.45
- GRFS $5.30
- 52 Week High
- WFRD $135.00
- GRFS $9.96
- Technical
- Relative Strength Index (RSI)
- WFRD 41.69
- GRFS 54.19
- Support Level
- WFRD $65.92
- GRFS $7.35
- Resistance Level
- WFRD $74.33
- GRFS $7.61
- Average True Range (ATR)
- WFRD 3.33
- GRFS 0.21
- MACD
- WFRD 0.41
- GRFS 0.07
- Stochastic Oscillator
- WFRD 36.24
- GRFS 82.35
About WFRD Weatherford International plc
Weatherford International provides diversified oilfield services across international markets for an array of oilfield types. The firm is a global market leader in artificial lift and tubular running services. Other key product lines include cementing products, directional drilling, and wireline evaluation.
About GRFS Grifols S.A.
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.